Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Core Insights - Praxis Precision Medicines has submitted two New Drug Applications (NDAs) for ulixacaltamide and relutrigine, targeting essential tremor and developmental and epileptic encephalopathies respectively, with pre-launch activities expected to accelerate through 2026 [1][3][4] - The company reported a significant increase in cash and investments, totaling $926 million as of December 31, 2025, and net proceeds of $621 million from a public offering in January 2026, which will fund operations into 2028 [10][11] Company Updates - The CEO highlighted a successful fourth quarter with multiple clinical and regulatory advancements, positioning the company for a transition into a commercial entity pending positive reviews of the NDAs [3] - Praxis is scaling its commercial organization and preparing for the launch of ulixacaltamide and relutrigine, including building inventory and initiating disease awareness campaigns [6][10] Financial Performance - As of December 31, 2025, Praxis reported cash, cash equivalents, and marketable securities of $926.1 million, a substantial increase from $469.5 million in 2024, primarily due to proceeds from a public offering [10] - Research and development expenses for Q4 2025 were $77.5 million, up from $56.3 million in Q4 2024, with total R&D expenses for the year reaching $267.1 million compared to $152.4 million in 2024 [11][12] - The company incurred a net loss of $88.9 million for Q4 2025, compared to a loss of $58.7 million in Q4 2024, and a total net loss of $303.3 million for the year [14][29] Product Development - Ulixacaltamide is the first investigational therapy to show positive results in a Phase 3 program for essential tremor, with Breakthrough Therapy Designation granted by the FDA [4][17] - Relutrigine has been granted Breakthrough Therapy Designation and Orphan Drug Designation by the FDA, targeting sodium channel modulation for developmental epileptic encephalopathies [5][19] - Vormatrigine, another product in development, is positioned as a best-in-class therapy for focal onset seizures and generalized epilepsy, with topline results expected in 2026 [8][11] Upcoming Milestones - Praxis plans to present results from the Essential3 program at the American Academy of Neurology Annual Meeting in April 2026, which will further support the launch of ulixacaltamide [4][6] - The EMERALD study for relutrigine is progressing well, with full enrollment expected in the second half of 2026, potentially leading to a supplemental NDA submission in 2027 [6][10]